PL2632927T3 - Boroniany jako inhibitory arginazy - Google Patents

Boroniany jako inhibitory arginazy

Info

Publication number: PL2632927T3
Authority: PL; Poland
Prior art keywords: boronates; arginase inhibitors; arginase; inhibitors
Prior art date: 2010-10-26

Application number

PL11779904.9T

Other languages

English (en)

Inventor

Zandt Michael Van

Jr. Gunnar Erik Jagdmann

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-26

Filing date

2011-10-19

Publication date

2016-09-30

2011-10-19 Application filed filed Critical

2016-09-30 Publication of PL2632927T3 publication Critical patent/PL2632927T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL11779904.9T 2010-10-26 2011-10-19 Boroniany jako inhibitory arginazy PL2632927T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US40676010P	2010-10-26	2010-10-26

Publications (1)

Publication Number	Publication Date
PL2632927T3 true PL2632927T3 (pl)	2016-09-30

Family

ID=44913403

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11779904.9T PL2632927T3 (pl)	2010-10-26	2011-10-19	Boroniany jako inhibitory arginazy

Country Status (19)

Country	Link
US (5)	US9233985B2 (pl)
EP (3)	EP3034509B1 (pl)
JP (1)	JP5909239B2 (pl)
CN (2)	CN103249737B (pl)
AU (1)	AU2011320732B2 (pl)
BR (1)	BR112013010099B1 (pl)
CA (1)	CA2815536C (pl)
DK (1)	DK2632927T3 (pl)
ES (2)	ES2568680T3 (pl)
HK (1)	HK1223104A1 (pl)
HR (1)	HRP20160305T1 (pl)
HU (1)	HUE027317T2 (pl)
IL (1)	IL225926A (pl)
MX (1)	MX336381B (pl)
PL (1)	PL2632927T3 (pl)
RS (1)	RS54750B1 (pl)
SI (1)	SI2632927T1 (pl)
SM (1)	SMT201600141B (pl)
WO (1)	WO2012058065A1 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX348422B (es)	2010-04-22	2017-06-12	Mars Inc	Inhibidores de arginasa y sus aplicaciones terapeuticas.
EP2603514B1 (en)	2010-08-10	2018-07-18	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
DK2632927T3 (en)	2010-10-26	2016-04-11	Mars Inc	Boronates AS ARGINSASEINHIBITORER
CA2870526C (en) *	2012-04-18	2020-05-05	Mars, Incorporated	Ring constrained analogs as arginase inhibitors
JP2016509594A (ja)	2013-01-04	2016-03-31	レンペックス・ファーマシューティカルズ・インコーポレイテッド	ボロン酸誘導体及びその治療的使用
US11624093B2 (en)	2014-04-24	2023-04-11	Dana-Farber Cancer Institute, Inc.	Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
US9687497B1 (en)	2014-05-05	2017-06-27	Rempex Pharmaceuticals, Inc.	Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
RS59488B1 (sr)	2014-05-05	2019-12-31	Rempex Pharmaceuticals Inc	Sinteza boronatnih soli i njihove upotrebe
MX2016015093A (es)	2014-05-19	2017-03-27	Rempex Pharmaceuticals Inc	Derivados de acido boronico y sus usos terapeuticos.
EA201692301A1 (ru)	2014-07-01	2017-06-30	Ремпекс Фармасьютикалз, Инк.	Производные бороновой кислоты и их терапевтическое применение
US10662205B2 (en)	2014-11-18	2020-05-26	Qpex Biopharma, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
PL410665A1 (pl)	2014-12-29	2016-07-04	Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory arginazy oraz ich zastosowania terapeutyczne
US20180051041A1 (en)	2015-03-17	2018-02-22	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
US10143699B2 (en)	2015-06-23	2018-12-04	Calithera Biosciences, Inc.	Compositions and methods for inhibiting arginase activity
SG10201912736UA (en)	2015-10-01	2020-02-27	Potenza Therapeutics Inc	Anti-tigit antigen-binding proteins and methods of use thereof
US10065974B2 (en) *	2015-10-30	2018-09-04	Calithera Biosciences, Inc.	Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) *	2016-05-04	2017-11-06	Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3478693B1 (en)	2016-06-30	2021-07-21	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
EP3538111B1 (en) *	2016-11-08	2022-01-19	Calithera Biosciences, Inc.	Arginase inhibitor combination therapies
ES2970715T3 (es) *	2016-12-22	2024-05-30	Prec Pharmaceuticals Inc	Composiciones y métodos para inhibir la actividad de la arginasa
WO2018166855A1 (en)	2017-03-16	2018-09-20	Basf Se	Heterobicyclic substituted dihydroisoxazoles
JOP20190203A1 (ar)	2017-03-30	2019-09-03	Potenza Therapeutics Inc	بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
AU2018265873A1 (en)	2017-05-12	2019-11-28	Calithera Biosciences, Inc.	Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide
JP7377545B2 (ja)	2017-10-11	2023-11-10	キューペックスバイオファーマ，インコーポレイテッド	ボロン酸誘導体およびその合成
CN111491937A (zh) *	2017-12-22	2020-08-04	广东新契生物医药科技有限公司	作为精氨酸酶抑制剂的杂环化合物
CR20200418A (es)	2018-02-17	2020-10-27	Astrazeneca Ab	Inhibidores de orginasa y sus mètodos de uso antecedentes
KR102656571B1 (ko) *	2018-03-05	2024-04-11	아르커스 바이오사이언시즈 인코포레이티드	아르기나아제 억제제
US12215116B2 (en) *	2018-03-13	2025-02-04	Merck Sharp & Dohme Llc	Arginase inhibitors and methods of use
PL3774843T3 (pl) *	2018-03-29	2022-11-14	Molecure Sa	Dipeptydowe pochodne piperydyny
CA3097127A1 (en)	2018-04-20	2019-10-24	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
CN111770756B (zh) *	2018-04-27	2023-03-31	四川科伦博泰生物医药股份有限公司	非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) *	2018-05-18	2019-11-21	四川科伦博泰生物医药股份有限公司	非天然氨基酸类衍生物、其制备方法及用途
WO2019245890A1 (en)	2018-06-20	2019-12-26	Merck Sharp & Dohme Corp.	Arginase inhibitors and methods of use
WO2020102646A2 (en) *	2018-11-16	2020-05-22	Arcus Biosciences, Inc.	Inhibitors of arg1 and/or arg2
US11034669B2 (en)	2018-11-30	2021-06-15	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
US12240867B2 (en)	2018-12-18	2025-03-04	Merck Sharp & Dohme Llc	Arginase inhibitors and methods of use
EP3917936A4 (en) *	2019-02-06	2022-12-14	Guangdong Newopp Biopharmaceuticals Co., Ltd.	ALKYBORONIC ACIDS AS ARGINASE INHIBITORS
PT3921033T (pt)	2019-02-08	2023-10-11	Astrazeneca Ab	Inibidores de arginase e métodos de utilização dos mesmos
AU2020319132B2 (en) *	2019-07-23	2023-09-07	Astrazeneca Ab	Arginase inhibitors and methods of use thereof
CN110734456A (zh) *	2019-11-06	2020-01-31	南京谷睿生物科技有限公司	一种化合物及其制备方法和医药上的应用
EP4087583A4 (en) *	2020-01-07	2024-01-24	Merck Sharp & Dohme LLC	Arginase inhibitors and methods of use
WO2021257863A1 (en)	2020-06-19	2021-12-23	Incyte Corporation	Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en)	2020-06-19	2021-12-23	Incyte Corporation	Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en)	2020-07-02	2023-09-26	Incyte Corporation	Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022006457A1 (en)	2020-07-02	2022-01-06	Incyte Corporation	Tricyclic urea compounds as jak2 v617f inhibitors
WO2022046989A1 (en)	2020-08-27	2022-03-03	Incyte Corporation	Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en)	2020-12-21	2024-03-05	Incyte Corporation	Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh)	2020-12-22	2022-08-01	波蘭商昂科艾倫迪治療法股份公司	精胺酸酶抑制劑及其使用方法
WO2022182839A1 (en)	2021-02-25	2022-09-01	Incyte Corporation	Spirocyclic lactams as jak2 v617f inhibitors
WO2023283332A1 (en) *	2021-07-07	2023-01-12	Emory University	Uses of arginase inhibitors for managing kidney disease and cardiovascular conditions
US20250099408A1 (en)	2022-01-21	2025-03-27	Sammy Oyoo OPIYO	Improved suramin methods and compositions
JP2025509672A (ja)	2022-03-17	2025-04-11	インサイト・コーポレイション	Ｊａｋ２ｖ６１７ｆ阻害剤としての三環式尿素化合物
US20240190876A1 (en)	2022-10-21	2024-06-13	Incyte Corporation	Tricyclic Urea Compounds As JAK2 V617F Inhibitors
CN121079299A (zh)	2023-03-13	2025-12-05	因赛特公司	作为激酶抑制剂的双环脲

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1009890A (en)	1911-02-09	1911-11-28	Michael F Brauer	Dumping attachment for headers.
US1006597A (en)	1911-05-26	1911-10-24	Rail Joint Co	Insulated rail-joint.
US4172896A (en)	1978-06-05	1979-10-30	Dainippon Pharmaceutical Co., Ltd.	Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en)	1992-08-14	1992-09-30	Wellcome Found	Controlled released tablets
US5358970A (en)	1993-08-12	1994-10-25	Burroughs Wellcome Co.	Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en)	1993-07-30	1996-07-30	Glaxo Wellcome Inc.	Stabilized Pharmaceutical
CN100408100C (zh)	1997-07-29	2008-08-06	阿尔康实验室公司	含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
WO1999019295A1 (en) *	1997-10-10	1999-04-22	Trustees Of The University Of Pennsylvania	Compositions and methods for inhibiting arginase activity
US20040063666A1 (en)	1998-10-09	2004-04-01	David Christianson	Compositions for inhibiting arginase activity
WO2002004465A1 (en)	2000-07-06	2002-01-17	Fal Diagnostics	Methods and kits for the detection of arginine compounds
CA2431080A1 (en)	2003-06-02	2004-12-02	Catherine Adele O'brien	Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en)	2003-07-01	2005-08-23	Allergan, Inc.	Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20090298912A1 (en)	2005-07-01	2009-12-03	The Johns Hopkins University	Arginase II: A Target treatment of aging heart and heart failure
CA2669300A1 (en)	2006-11-21	2008-05-29	Rijksuniversiteit Groningen	Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
US20100189544A1 (en)	2007-07-12	2010-07-29	Sanyo Denki Co., Ltd.	Counter-rotating axial-flow fan
KR20150115959A (ko)	2007-10-12	2015-10-14	레솔빅스 파마슈티칼즈, 인코퍼레이티드	안과 질환의 치료를 위한 옥실리핀 화합물
MX2010012064A (es)	2008-05-05	2010-12-06	Schering Corp	Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
JP2012515799A (ja)	2009-01-26	2012-07-12	ザトラスティーズオブザユニバーシティオブペンシルバニア	アルギナーゼ阻害剤および使用方法
MX348422B (es)	2010-04-22	2017-06-12	Mars Inc	Inhibidores de arginasa y sus aplicaciones terapeuticas.
DK2632927T3 (en) *	2010-10-26	2016-04-11	Mars Inc	Boronates AS ARGINSASEINHIBITORER
US8894970B2 (en)	2010-12-31	2014-11-25	Corridor Pharmaceuticals, Inc.	Arginase inhibitors and methods of use thereof
CA2852685C (en)	2011-10-19	2019-02-26	Mars, Incorporated	Inhibitors of arginase and their therapeutic application
WO2013059587A1 (en)	2011-10-20	2013-04-25	Sirtris Pharmaceuticals, Inc.	Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
CA2870526C (en)	2012-04-18	2020-05-05	Mars, Incorporated	Ring constrained analogs as arginase inhibitors
EA201590822A1 (ru)	2012-11-02	2016-01-29	Фармасайкликс, Инк.	Адъювантная терапия ингибитором киназы семейства tec
EA029126B1 (ru)	2013-07-01	2018-02-28	Бристол-Майерс Сквибб Компани	Ингибиторы ido
JP6508785B2 (ja)	2013-10-25	2019-05-08	ファーマサイクリックスエルエルシー	ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
CN105879030A (zh)	2014-09-30	2016-08-24	复旦大学	治疗肿瘤的增效药物复合物及其制备方法
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
WO2016153078A1 (en)	2015-03-20	2016-09-29	Opiyo Sammy Oyoo	Use of suramin and arginase inhibitors in malignant neoplasia
US10143699B2 (en)	2015-06-23	2018-12-04	Calithera Biosciences, Inc.	Compositions and methods for inhibiting arginase activity
US10065974B2 (en)	2015-10-30	2018-09-04	Calithera Biosciences, Inc.	Compositions and methods for inhibiting arginase activity
PL417066A1 (pl)	2016-05-04	2017-11-06	Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory arginazy oraz ich zastosowania terapeutyczne
ES2970715T3 (es)	2016-12-22	2024-05-30	Prec Pharmaceuticals Inc	Composiciones y métodos para inhibir la actividad de la arginasa
AU2018265873A1 (en)	2017-05-12	2019-11-28	Calithera Biosciences, Inc.	Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide

2011
- 2011-10-19 DK DK11779904.9T patent/DK2632927T3/en active
- 2011-10-19 HU HUE11779904A patent/HUE027317T2/en unknown
- 2011-10-19 MX MX2013004491A patent/MX336381B/es unknown
- 2011-10-19 EP EP16150285.1A patent/EP3034509B1/en active Active
- 2011-10-19 RS RS20160243A patent/RS54750B1/sr unknown
- 2011-10-19 JP JP2013536669A patent/JP5909239B2/ja active Active
- 2011-10-19 EP EP20162218.0A patent/EP3719024A1/en active Pending
- 2011-10-19 BR BR112013010099-0A patent/BR112013010099B1/pt not_active IP Right Cessation
- 2011-10-19 WO PCT/US2011/056844 patent/WO2012058065A1/en not_active Ceased
- 2011-10-19 EP EP11779904.9A patent/EP2632927B1/en active Active
- 2011-10-19 CN CN201180057717.4A patent/CN103249737B/zh not_active Expired - Fee Related
- 2011-10-19 AU AU2011320732A patent/AU2011320732B2/en not_active Ceased
- 2011-10-19 SI SI201130766A patent/SI2632927T1/sl unknown
- 2011-10-19 ES ES11779904.9T patent/ES2568680T3/es active Active
- 2011-10-19 CN CN201610322649.4A patent/CN106008569B9/zh not_active Expired - Fee Related
- 2011-10-19 PL PL11779904.9T patent/PL2632927T3/pl unknown
- 2011-10-19 CA CA2815536A patent/CA2815536C/en active Active
- 2011-10-19 ES ES16150285T patent/ES2794006T3/es active Active
- 2011-10-19 US US13/276,806 patent/US9233985B2/en active Active
- 2011-10-19 HR HRP20160305TT patent/HRP20160305T1/hr unknown
2013
- 2013-04-24 IL IL225926A patent/IL225926A/en active IP Right Grant
2015
- 2015-02-04 US US14/614,115 patent/US9440995B2/en active Active
2016
- 2016-05-19 SM SM201600141T patent/SMT201600141B/it unknown
- 2016-07-12 US US15/207,902 patent/US10098902B2/en active Active
- 2016-09-23 HK HK16111212.1A patent/HK1223104A1/en unknown
2018
- 2018-08-21 US US16/107,087 patent/US10603330B2/en not_active Expired - Fee Related
2020
- 2020-02-19 US US16/794,905 patent/US11389464B2/en active Active

Also Published As

Publication number	Publication date
AU2011320732A1 (en)	2013-11-21
CN103249737B (zh)	2016-06-08
CN106008569B9 (zh)	2020-05-22
DK2632927T3 (en)	2016-04-11
JP2013542223A (ja)	2013-11-21
EP2632927B1 (en)	2016-02-10
AU2011320732B2 (en)	2018-07-05
EP3719024A1 (en)	2020-10-07
US10603330B2 (en)	2020-03-31
BR112013010099A2 (pt)	2016-09-06
EP3034509A1 (en)	2016-06-22
US20200246362A1 (en)	2020-08-06
US20120129806A1 (en)	2012-05-24
MX2013004491A (es)	2013-11-04
EP2632927A1 (en)	2013-09-04
JP5909239B2 (ja)	2016-04-26
HK1225390A1 (zh)	2017-09-08
CA2815536C (en)	2019-10-01
EP3034509B1 (en)	2020-04-22
HUE027317T2 (en)	2016-10-28
IL225926A (en)	2016-09-29
BR112013010099B1 (pt)	2021-08-10
MX336381B (es)	2016-01-18
CN106008569B (zh)	2020-04-03
HK1223104A1 (en)	2017-07-21
HRP20160305T1 (hr)	2016-07-01
CN103249737A (zh)	2013-08-14
CN106008569A (zh)	2016-10-12
US20150191492A1 (en)	2015-07-09
US10098902B2 (en)	2018-10-16
US20170000808A1 (en)	2017-01-05
ES2794006T3 (es)	2020-11-17
US11389464B2 (en)	2022-07-19
US9440995B2 (en)	2016-09-13
SMT201600141B (it)	2016-07-01
US9233985B2 (en)	2016-01-12
SI2632927T1 (sl)	2016-08-31
WO2012058065A1 (en)	2012-05-03
RS54750B1 (sr)	2016-10-31
IL225926A0 (en)	2013-06-27
ES2568680T3 (es)	2016-05-03
CA2815536A1 (en)	2012-05-03
US20190054101A1 (en)	2019-02-21

Publication	Publication Date	Title
SI2632927T1 (sl)	2016-08-31	Boronati kot inhibitorji arginaze
TWI560172B (en)	2016-12-01	Neprilysin inhibitors
ZA201304205B (en)	2014-02-26	Neprilysin inhibitors
GB201004179D0 (en)	2010-04-28	Enzyme inhibitors
ZA201305826B (en)	2014-04-30	Substituted amminobutyric derivatives as neprilysin inhibitors
ZA201304208B (en)	2014-02-26	Neprilysin inhibitors
ZA201306580B (en)	2014-05-28	Cyclopropylamines as lsd1 inhibitors
GB201004178D0 (en)	2010-04-28	Enzyme inhibitors
PT2563771E (pt)	2016-03-31	Compostos inibidores de metaloenzimas
GB201004311D0 (en)	2010-04-28	New enzyme inhibitor compounds
GB201016880D0 (en)	2010-11-17	Phosphodiesterase inhibitors
AP3529A (en)	2016-01-11	Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
ZA201206456B (en)	2013-05-29	Uses of dgati inhibitors
GB201018996D0 (en)	2010-12-22	Novel ROCK inhibitors
ZA201303360B (en)	2014-07-30	Kat ii inhibitors
EP2521451A4 (en)	2013-08-21	INHIBITORS OF THE HEDGEHOG PATH
EP2632903A4 (en)	2014-11-26	METALLOENZYMHEMMERVERBINDUNGEN
GB201020798D0 (en)	2011-01-19	Corrosion inhibitors
EP2651905A4 (en)	2014-05-07	METALLOENZYMHEMMERVERBINDUNGEN
ZA201303412B (en)	2014-07-30	Kat ii inhibitors
GB201113689D0 (en)	2011-09-21	Novel PDE4 inhibitors
PL2558462T3 (pl)	2015-03-31	Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
GB201003936D0 (en)	2010-04-21	Novel inhibitors
GB201006605D0 (en)	2010-06-02	Novel inhibitors
GB201003502D0 (en)	2010-04-14	Novel inhibitors